Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,783,424
  • Shares Outstanding, K 220,448
  • Annual Sales, $ 0 K
  • Annual Income, $ -283,260 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.22
Trade SANA with:

Options Overview Details

View History
  • Implied Volatility 141.55% ( +16.26%)
  • Historical Volatility 74.48%
  • IV Percentile 78%
  • IV Rank 48.89%
  • IV High 271.50% on 12/28/23
  • IV Low 17.26% on 10/25/23
  • Put/Call Vol Ratio 0.19
  • Today's Volume 82
  • Volume Avg (30-Day) 386
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 8,089
  • Open Int (30-Day) 10,861

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.33
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +30.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.25 +18.34%
on 04/19/24
10.18 -15.72%
on 04/01/24
-0.57 (-6.23%)
since 03/22/24
3-Month
5.22 +64.37%
on 01/29/24
12.00 -28.50%
on 03/01/24
+3.26 (+61.28%)
since 01/24/24
52-Week
2.74 +212.57%
on 10/27/23
12.00 -28.50%
on 03/01/24
+3.55 (+70.58%)
since 04/24/23

Most Recent Stories

More News
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 15.56 (-3.41%)
FHTX : 5.21 (+0.97%)
MRNA : 108.85 (+0.89%)
OMGA : 2.33 (-0.43%)
SANA : 8.58 (+6.06%)
MCRB : 0.7295 (-4.01%)
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?

The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.

CI : 352.28 (-0.10%)
BIO : 278.21 (-2.48%)
BRBR : 55.62 (-0.98%)
SANA : 8.58 (+6.06%)
Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend...

SANA : 8.58 (+6.06%)
Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 78.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend...

SANA : 8.58 (+6.06%)
2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?

Good news drove shares of these stocks through the roof last week, but investors should be more concerned about their paths forward.

COMP : 3.33 (-2.35%)
SANA : 8.58 (+6.06%)
BKD : 6.75 (-2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 9.37
2nd Resistance Point 8.99
1st Resistance Point 8.79
Last Price 8.58
1st Support Level 8.21
2nd Support Level 7.83
3rd Support Level 7.63

See More

52-Week High 12.00
Last Price 8.58
Fibonacci 61.8% 8.46
Fibonacci 50% 7.37
Fibonacci 38.2% 6.28
52-Week Low 2.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar